Technology & Innovation Development Office (TIDO) of Boston Children’s Hospital just released its fiscal year 2019 (FY19) annual report on December 12th, 2020. In TIDO’s FY19 report, Edelweiss Immune was highlighted as featured Start-up Biotech that originated from the IP of Boston Children’s Hospital.
See details: http://tido.childrenshospital.org/
